title: Chemoprevention of breast cancer.
authors.affiliation: Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: O'Regan
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects; D001941:Breast Diseases / Q000453:epidemiology; D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D004967:Estrogens; D005260:Female; D012739:Gonadal Steroid Hormones / Q000032:analysis; D006801:Humans; D008055:Lipids / Q000097:blood; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000517:prevention & control; D051379:Mice; D008809:Mice, Inbred C3H; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009376:Neoplasms, Hormone-Dependent / Q000453:epidemiology / Q000517:prevention & control*; D016609:Neoplasms, Second Primary / Q000453:epidemiology; D009386:Neoplastic Syndromes, Hereditary / Q000453:epidemiology; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010865:Pilot Projects; D011230:Precancerous Conditions / Q000453:epidemiology; D017697:Premenopause; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000187:drug effects; D017584:Reproductive History; D012307:Risk Factors; D012449:Safety; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016588:Anticarcinogenic Agents; D004967:Estrogens; D012739:Gonadal Steroid Hormones; D008055:Lipids; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride